ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR STAGES 3 AND 4 PROLIFERATIVE SICKLE CELL RETINOPATHY RESULTS IN IMPROVED ANATOMICAL AND VISUAL OUTCOMES
Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.
Authors
- Jennifer I. Lim (ORCID: https://orcid.org/0000-0001-7791-6998)
- Ogugua Ndubuisi Okonkwo (ORCID: https://orcid.org/0000-0002-6805-2427)
- Adrienne W. Scott (ORCID: https://orcid.org/0000-0003-2607-1184)
- J. Cao (ORCID: https://orcid.org/0009-0003-8237-6684)
- Bita Momenaei (ORCID: https://orcid.org/0000-0002-5435-7369)
- Bernadette A. Miao (ORCID: https://orcid.org/0000-0002-3123-0111)
- Sally Shin Yee Ong (ORCID: https://orcid.org/0000-0003-3599-9021)
- Carl D. Regillo (ORCID: https://orcid.org/0000-0001-8260-9925)
- Jinyun Liu (ORCID: https://orcid.org/0000-0002-4763-2684)
- Alicia Chen (ORCID: https://orcid.org/0000-0003-0222-5193)
- Charles C. Wykoff
Institutions
- Atrium Health Wake Forest Baptist (US)
- Johns Hopkins University (US)
- New York Eye and Ear Infirmary (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- Retina Consultants of Texas (US)
- Johns Hopkins Hospital (US)
- Smith-Kettlewell Eye Research Institute (US)
- Wake Forest University (US)
- Wills Eye Hospital (US)
Publication Details
- Journal
- Retina
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1097/iae.0000000000004658
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Research to Prevent Blindness
- Sanofi
- Regeneron Pharmaceuticals
- REGENXBIO
- BioCryst
- Alimera Sciences
- Apellis Pharmaceuticals
- Aldeyra Therapeutics
- Santen
- Astellas Pharma
- Genentech
- Allergan